Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Kissei’s ITP Med Tavalisse Now Available in Japan
Kissei Pharmaceutical rolled out Tavalisse (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor licensed from Rigel Pharmaceuticals, for the treatment of chronic immune thrombocytopenic purpura (ITP) in Japan on April 6. The Japanese company acquired the development and commercialization rights…
To read the full story
Related Article
- Tavalisse Now Available in South Korea for Chronic ITP: Kissei
July 2, 2025
- ITP Drug Tavalisse Approved in South Korea: Kissei
January 22, 2025
- Mitsubishi Tanabe Gets Taiwan Rights for Rigel/Kissei’s ITP Drug
January 8, 2025
- Kissei Snares Rigel’s AML Therapy in Japan, Korea, Taiwan
September 5, 2024
- Kissei Files Fostamatinib, Orphan Drug for ITP, in Japan
April 28, 2022
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…